Compare REG & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REG | JAZZ |
|---|---|---|
| Founded | 1963 | 2003 |
| Country | United States | Ireland |
| Employees | 507 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 16.1B |
| IPO Year | N/A | 2007 |
| Metric | REG | JAZZ |
|---|---|---|
| Price | $77.59 | $256.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $80.07 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 1.3M | 697.4K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $3.04 | $6.22 |
| Revenue Next Year | $4.52 | $7.68 |
| P/E Ratio | ★ $26.85 | $36.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $66.86 | $109.87 |
| 52 Week High | $83.66 | $265.05 |
| Indicator | REG | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 65.75 |
| Support Level | $78.66 | $222.49 |
| Resistance Level | $79.72 | N/A |
| Average True Range (ATR) | 1.27 | 7.12 |
| MACD | -0.37 | 0.46 |
| Stochastic Oscillator | 19.03 | 90.54 |
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.